SAN DIEGO, April 7, 2025 /PRNewswire/ --

UNITED STATES DISTRICT COURTSOUTHERN DISTRICT OF CALIFORNIA

IN RE IMMUNITYBIO, INC.                                             SECURITIES LITIGATION

No. 3:23-cv-01216-GPC-VET

NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION

TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR ACQUIRED IMMUNITYBIO, INC. ("IMMUNITYBIO") (NASDAQ: IBRX) SECURITIES BETWEEN MARCH 10, 2021, AND MAY 10, 2023, BOTH DATES INCLUSIVE.

YOU ARE HEREBY NOTIFIED, pursuant to an Order of the United States District Court for the Southern District of California (the "Court"), that a hearing will be held on June 13, 2025, at 1:30 p.m. before the Honorable Gonzalo P. Curiel, United States District Judge of the United States District Court for the Southern District of California, at the Edward J. Schwartz United States Courthouse, 221 West Broadway, San Diego, California 92101 for the purpose of determining: (1) whether the proposed Settlement of the claims in the above-captioned Action for consideration in the amount of ten million five hundred thousand dollars ($10,500,000.00) should be approved by the Court as fair, reasonable, and adequate; (2) whether the Plan of Allocation for distributing the proceeds from the proposed Settlement is fair and reasonable, and should be approved; (3) whether Co-Lead Counsel's application for an award of attorneys' fees, reimbursement of out-of-pocket expenses plus interest, and a compensatory award for Lead Plaintiff, all to be paid from the Settlement Fund, should be granted, and, if so, in what amount; and (4) whether the proposed Judgment should be entered and this Action should be dismissed with prejudice against the Defendants as set forth in the Stipulation of Settlement dated January 28, 2025 (the "Stipulation") filed with the Court.

FREMONT, Calif., Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration agreement aimed at automating and streamlining the data fulfillment process for clinical trials. The goal of the collaboration is to make this essential process easier, faster, and less expensive for ImmunityBio's trial investigators.

SAN FRANCISCO, Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2023 to secure regulatory approval for its flagship product Anktiva, designed to treat bladder cancer. Current shareholders are encouraged to contact the firm.

On June 20, 2024, Judge Gonzalo P. Curiel of the U.S. District Court for the Southern District of California issued an order denying in part a motion to dismiss a class action complaint filed against ImmunityBio and certain of its executive officers. There, it is alleged that biotechnology company ImmunityBio intentionally misled investors between March 2021 and May 2023 about the prospects of obtaining U.S. Food and Drug Administration approval for Anktiva by concealing known recordkeeping, quality control, and sanitation problems at its contract manufacturer. When the truth was revealed in May 2023, ImmunityBio's stock fell 55%.

NEW ORLEANS, July 12, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX).

On May 11, 2023, the Company disclosed that it had received a complete response letter ("CRL") from the FDA stating that, among other things, it could not approve the company's Biologics License Application ("BLA") for its flagship product candidate, an antibody called N-803, known internally as Anktiva, due to deficient manufacturing practices.